{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T22:15:51Z","timestamp":1768774551587,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"crossref","award":["510337"],"award-info":[{"award-number":["510337"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.breast.2013.04.011","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T08:17:29Z","timestamp":1368087449000},"page":"482-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function?"],"prefix":"10.1016","volume":"22","author":[{"given":"Christine Y.","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeyaporn","family":"Srasuebkul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K.","family":"Drew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn L.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sallie-Anne","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2013.04.011_bib1","series-title":"Breast cancer incidence and mortality worldwide in 2008","author":"GLOBOCAN","year":"2008"},{"key":"10.1016\/j.breast.2013.04.011_bib2","unstructured":"American Cancer Society. Breast cancer facts & figures 2011\u20132012. http:\/\/www.cancer.org\/Research\/CancerFactsFigures\/BreastCancerFactsFigures\/breast-cancer-facts-and-figures-2011-2012 [accessed 05.09.12]."},{"key":"10.1016\/j.breast.2013.04.011_bib3","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/annonc\/mdq607","article-title":"Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?","volume":"22","author":"Verma","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.04.011_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.04.011_bib5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2007.14.8742","article-title":"Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?","volume":"26","author":"Ewer","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.04.011_bib6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10549-007-9877-0","article-title":"Cardiotoxicity and anthracyclines","volume":"107","author":"Stebbing","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.04.011_bib7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2013.04.011_bib8","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2013.04.011_bib9","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.breast.2013.04.011_bib10","volume":"94","author":"Slamon","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.04.011_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2013.04.011_bib12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2013.04.011_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3747\/co.2008.199","article-title":"Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group","volume":"15","author":"Mackey","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2013.04.011_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","article-title":"Cardiotoxicity profile of trastuzumab","volume":"31","author":"Ewer","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.breast.2013.04.011_bib15","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","article-title":"Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience","volume":"24","author":"Guarneri","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.04.011_bib16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdr348","article-title":"Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors","volume":"23","author":"Serrano","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.04.011_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","article-title":"Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer","volume":"18","author":"Tarantini","year":"2012","journal-title":"J\u00a0Card Fail"},{"issue":"17","key":"10.1016\/j.breast.2013.04.011_bib18","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Aiello Bowles","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.04.011_bib19","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2007.11.2516","article-title":"Trastuzumab and metastatic breast cancer: trastuzumab use in Australia \u2013 monitoring the effect of an expensive medicine access program","volume":"25","author":"Pearson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.04.011_bib20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1634\/theoncologist.2009-0029","article-title":"Efficacy of trastuzumab in\u00a0routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study","volume":"15","author":"Extra","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2013.04.011_bib21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1524-4741.2011.01101.x","article-title":"Lack of uniformity in cardiac assessment during trastuzumab therapy","volume":"17","author":"Subar","year":"2011","journal-title":"Breast J"},{"key":"10.1016\/j.breast.2013.04.011_bib22","article-title":"Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer","author":"Allen","year":"2012","journal-title":"Med Care"},{"key":"10.1016\/j.breast.2013.04.011_bib23","series-title":"Early and locally advanced breast cancer: diagnosis and treatment (clinical guideline 80)","author":"UK National Institute for Health and Clinical Excellence","year":"2009"},{"key":"10.1016\/j.breast.2013.04.011_bib24","series-title":"Recommendations for use of trastuzumab (Herceptin) for the treatment of HER2-positive breast cancer","author":"Australian National Breast Cancer Centre","year":"2007"},{"key":"10.1016\/j.breast.2013.04.011_bib25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","article-title":"Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring","volume":"100","author":"Jones","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2013.04.011_bib26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","volume":"53","author":"Hunt","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.breast.2013.04.011_bib27","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1445-5994.2011.02604.x","article-title":"Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer","volume":"42","author":"Lu","year":"2012","journal-title":"Intern Med J"},{"key":"10.1016\/j.breast.2013.04.011_bib28","series-title":"SEIFA: socio-economic indexes for areas","author":"Australian Bureau of Statistics","year":"2006"},{"key":"10.1016\/j.breast.2013.04.011_bib29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/01.MLR.0000064641.84967.B7","article-title":"Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument","volume":"41","author":"Sloan","year":"2003","journal-title":"Med Care"},{"key":"10.1016\/j.breast.2013.04.011_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jclinepi.2010.02.015","article-title":"Charlson and Rx-risk comorbidity indices were predictive of mortality in the Australian health care setting","volume":"64","author":"Lu","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.breast.2013.04.011_bib31","first-page":"117","article-title":"Zero-inflated generalized Poisson regression model with an application to domestic violence data","volume":"4","author":"Famoye","year":"2006","journal-title":"J\u00a0Data Sci"},{"key":"10.1016\/j.breast.2013.04.011_bib32","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jnci\/97.12.870","article-title":"Trastuzumab trials steal show at ASCO meeting","volume":"97","author":"Tuma","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.04.011_bib33","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J\u00a0Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613000921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613000921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:30:23Z","timestamp":1760776223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977613000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0960977613000921"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2013.04.011","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function?","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2013.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}